{"id":1307,"date":"2025-08-06T23:47:42","date_gmt":"2025-08-06T23:47:42","guid":{"rendered":"https:\/\/720degrees.ai\/?page_id=1307"},"modified":"2025-08-12T18:32:23","modified_gmt":"2025-08-12T18:32:23","slug":"source","status":"publish","type":"page","link":"https:\/\/720degrees.ai\/pt\/source\/","title":{"rendered":"Source"},"content":{"rendered":"
\n\t\t
\n\t\t\t\t\t\t\t\t\t\n\t\t\t\n\n\t\t<\/div>\n\n\t\t\n\n\t\t
\n\t\t\t\n
\n\n\t
\n\t\t\t\t
\n\t\t\t\n\t\t\t\n\n[
\n {
\n “ProductName”: “IVAHART”,
\n “RegularizationNumber”: “105250090”,
\n “RegularizationDate”: “07\/06\/2021”,
\n “CNPJ”: “33.078.528\/0001-32”,
\n “CaseNumber”: “25351.679486\/2018-91”,
\n “RegularizationDueDate”: “06\/2031”,
\n “CloneDetails”: “{“Clones”: [{“Name”: “cloridrato de ivabradina”, “Process Number”: “25351.866933\/2021-46”, “Clone URL”: “https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/2963585”}], “Clone”: “2. Clone Product Name: cloridrato de ivabradina\\n Clone Process Number:25351.866933\/2021-46\\n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/2963585″}”,
\n “ActiveIngredient”: “CLORIDRATO DE IVABRADINA”,
\n “Packaging”: “Prim\u00e1ria – Blister de alum\u00ednio e alum\u00ednionSecund\u00e1ria – Cartucho”,
\n “ManufacturingLocation”: “Fabricante: TORRENT PHARMACEUTICALS LTD.nC\u00f3digo \u00fanico: A001089nEndere\u00e7o: PLOT NO Z\/104 TO106 DAHEJ SEZ PART-II, TAL – VAGRA, DIST – BHARUCH -392130 – \u00cdndianEtapa de Fabrica\u00e7\u00e3o: Processo produtivo completo”,
\n “RouteofAdministration”: “ORAL”,
\n “Conservation”: “CONSERVAR EM TEMPERATURA AMBIENTE ( AMBIENTE COM TEMPERATURA ENTRE15 E30\u00baC)”,
\n “PrescriptionRestriction”: “Venda sob Prescri\u00e7\u00e3o M\u00e9dica”,
\n “Restrictionofuse”: “Adulto”,
\n “MatrixUpdateAlert”: “No Alert”,
\n “MatrixUpdateAlertDate”: “N\/A”,
\n “RegularizationExpirationAlert”: “No Alert”
\n },
\n {
\n “ProductName”: “rivaroxabana”,
\n “RegularizationNumber”: “105250080”,
\n “RegularizationDate”: “16\/09\/2019”,
\n “CNPJ”: “33.078.528\/0001-32”,
\n “CaseNumber”: “25351.201839\/2017-95”,
\n “RegularizationDueDate”: “09\/2029”,
\n “CloneDetails”: “{“Clones”: [{“Name”: “ACOG”, “Process Number”: “25351.230018\/2017-31”, “Clone URL”: “https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/1166654?cnpj=33078528000132&situacaoRegistro=V”}], “Clone Product Name”: “ACOG”, “Clone Process Number”: “25351.230018\/2017-31”, “Clone URL”: “https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/1166654?cnpj=33078528000132&situacaoRegistro=V”}”,
\n “ActiveIngredient”: “RIVAROXABANA”,
\n “Packaging”: “Prim\u00e1ria – Blister de alum\u00ednio e alum\u00ednionSecund\u00e1ria – Cartucho”,
\n “ManufacturingLocation”: “Fabricante: TORRENT PHARMACEUTICALS LIMITEDnC\u00f3digo \u00fanico: A000614nEndere\u00e7o: AHMEDABAD – MEHSANA HIGHWAY – TALUKA-KADI, DISTRICT MEHSANA, INDRAD382721 GUJARAT – \u00cdndianEtapa de Fabrica\u00e7\u00e3o: Processo produtivo completo”,
\n “RouteofAdministration”: “ORAL”,
\n “Conservation”: “CONSERVAR EM TEMPERATURA AMBIENTE ( AMBIENTE COM TEMPERATURA ENTRE15 E30\u00baC)nPROTEGER DA UMIDADE”,
\n “PrescriptionRestriction”: “Venda sob Prescri\u00e7\u00e3o M\u00e9dica”,
\n “Restrictionofuse”: “Adulto”,
\n “MatrixUpdateAlert”: “Annual Matrix update is due on 16\/09\/2025 which is within next 9 months. Please update it and also update the clones within 30 days of matrix update.”,
\n “MatrixUpdateAlertDate”: “16\/09\/2025”,
\n “RegularizationExpirationAlert”: “No Alert”
\n },
\n {
\n “ProductName”: “ARIPIPRAZOL”,
\n “RegularizationNumber”: “156490007”,
\n “RegularizationDate”: “01\/02\/2016”,
\n “CNPJ”: “05.399.786\/0001-85”,
\n “CaseNumber”: “25351.643872\/2012-43”,
\n “RegularizationDueDate”: “02\/2026”,
\n “CloneDetails”: “”,
\n “ActiveIngredient”: “ARIPIPRAZOL”,
\n “Packaging”: “Prim\u00e1ria – BLISTER DE ALUMINIO\/ALUMINIOnSecund\u00e1ria – CARTUCHO CARTAO”,
\n “ManufacturingLocation”: “Fabricante: UNICHEM LABORATORIES LIMITEDnC\u00f3digo \u00fanico: A000621nEndere\u00e7o: C-31 &32 & D-10, INDUSTRIAL AREA, MEERUT ROAD, GHAZIABAD201003 – \u00cdndianEtapa de Fabrica\u00e7\u00e3o:”,
\n “RouteofAdministration”: “ORAL”,
\n “Conservation”: “CONSERVAR EM TEMPERATURA AMBIENTE ( AMBIENTE COM TEMPERATURA ENTRE15 E30\u00baC)”,
\n “PrescriptionRestriction”: “Venda sob prescri\u00e7\u00e3o m\u00e9dica com reten\u00e7\u00e3o de receita”,
\n “Restrictionofuse”: “Adulto”,
\n “MatrixUpdateAlert”: “Annual Matrix update is due on 01\/02\/2026 which is within next 9 months. Please update it and also update the clones within 30 days of matrix update.”,
\n “MatrixUpdateAlertDate”: “01\/02\/2026”,
\n “RegularizationExpirationAlert”: “Regularization will expire on 02\/2026 which is within next 9 months. Please renew the regularization.”
\n },
\n {
\n “ProductName”: “telmisartana + hidroclorotiazida”,
\n “RegularizationNumber”: “155370096”,
\n “RegularizationDate”: “26\/04\/2021”,
\n “CNPJ”: “64.171.697\/0001-46”,
\n “CaseNumber”: “25351.188508\/2019-90”,
\n “RegularizationDueDate”: “04\/2031”,
\n “CloneDetails”: “2. Clone Product Name: telmisartana + hidroclorotiazidan Clone Process Number:25351.443146\/2024-72n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3780574n3. Clone Product Name: n\u00e3o registradon Clone Process Number:25351.007478\/2025-78n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3789733n4. Clone Product Name: telmisartana + hidroclorotiazidan Clone Process Number:25351.530547\/2023-81n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3646330n5. Clone Product Name: telmisartana + hidroclorotiazidan Clone Process Number:25351.140055\/2024-88n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3709105n6. Clone Product Name: telmisartana + hidroclorotiazidan Clone Process Number:25351.255796\/2022-09n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3297024n7. Clone Product Name: TELD HCTn Clone Process Number:25351.255786\/2022-65n Clone URL: https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3311890”,
\n “ActiveIngredient”: “TELMISARTANAnHIDROCLOROTIAZIDA”,
\n “Packaging”: “Prim\u00e1ria – Blister de alum\u00ednio e alum\u00ednionSecund\u00e1ria – Cartucho”,
\n “ManufacturingLocation”: “Fabricante: INTAS PHARMACEUTICALS LIMITEDnC\u00f3digo \u00fanico: A000704nEndere\u00e7o: PLOT5 A14- PHARMEZ ,BUILDING: B, C AND G, NEAR VILLAGE MATODA, TAL-SANAND, CITY: MATODA, DIST: AHMEDABAD, GUJARAT STATE – \u00cdndianEtapa de Fabrica\u00e7\u00e3o: Processo produtivo completo”,
\n “RouteofAdministration”: “ORAL”,
\n “Conservation”: “CONSERVAR EM TEMPERATURA AMBIENTE ( AMBIENTE COM TEMPERATURA ENTRE15 E30\u00baC)nPROTEGER DA UMIDADE”,
\n “PrescriptionRestriction”: “Venda sob Prescri\u00e7\u00e3o M\u00e9dica”,
\n “Restrictionofuse”: “Adulto”,
\n “MatrixUpdateAlert”: “Annual Matrix update is due on 26\/04\/2026 which is within next 9 months. Please update it and also update the clones within 30 days of matrix update.”,
\n “MatrixUpdateAlertDate”: “26\/04\/2026”,
\n “RegularizationExpirationAlert”: “No Alert”
\n },
\n {
\n “ProductName”: “OLMECOR HCT”,
\n “RegularizationNumber”: “105250114”,
\n “RegularizationDate”: “20\/05\/2024”,
\n “CNPJ”: “33.078.528\/0001-32”,
\n “CaseNumber”: “25351.255787\/2022-18”,
\n “RegularizationDueDate”: “05\/2034”,
\n “CloneDetails”: “{“Clones”: [{“Name”: “olmesartana medoxomila + hidroclorotiazida”, “Process Number”: “25351.393719\/2024-18”, “Clone URL”: “https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3801824?cnpj=33078528000132&situacaoRegistro=V”}], “Clone Product Name”: “olmesartana medoxomila + hidroclorotiazida”, “Clone Process Number”: “25351.393719\/2024-18”, “Clone URL”: “https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/3801824?cnpj=33078528000132&situacaoRegistro=V”}”,
\n “ActiveIngredient”: “OLMESARTANA MEDOXOMILAnHIDROCLOROTIAZIDA”,
\n “Packaging”: “Prim\u00e1ria – Blister de alum\u00ednio e alum\u00ednionSecund\u00e1ria – Cartucho”,
\n “ManufacturingLocation”: “Fabricante: TORRENT PHARMACEUTICALS LTD.nC\u00f3digo \u00fanico: A000615nEndere\u00e7o: VILLAGE BHUD & MAKHNU MAJRA, TEHSIL: BADDI-173205- DISTT. SOLAN (H.P) – \u00cdndianEtapa de Fabrica\u00e7\u00e3o: Processo produtivo completo”,
\n “RouteofAdministration”: “ORAL”,
\n “Conservation”: “CONSERVAR EM TEMPERATURA AMBIENTE ( AMBIENTE COM TEMPERATURA ENTRE15 E30\u00baC)”,
\n “PrescriptionRestriction”: “Venda sob Prescri\u00e7\u00e3o M\u00e9dica”,
\n “Restrictionofuse”: “Adulto”,
\n “MatrixUpdateAlert”: “No Alert”,
\n “MatrixUpdateAlertDate”: “N\/A”,
\n “RegularizationExpirationAlert”: “No Alert”
\n }
\n][
\n {
\n “Certified Company”: “INTAS PHARMACEUTICALS LIMITED”,
\n “Code. Unique \/ Certified CNPJ”: “A000704”,
\n “Certified Company Address”: “PLOT 5 A 14- PHARMEZ ,BUILDING: B, C AND G, NEAR VILLAGE MATODA, TAL-SANAND, CITY: MATODA, DIST: AHMEDABAD, GUJARAT STATE”,
\n “Country”: “\u00cdNDIA”,
\n “Requesting Company”: “TORRENT DO BRASIL LTDA”,
\n “CNPJ (Requesting Company)”: “33.078.528\/0001-32”,
\n “Requesting Company Address”: “AVENIDA TAMBOR\u00c9, N\u00b0 1180, M\u00d3DULOS A3, A4, A5 E A6.”,
\n “City \/ State”: “BARUERI \/ SP”,
\n “Subject”: “70512 – MEDICAMENTOS \u2013 RENOVA\u00c7\u00c3O (Certifica\u00e7\u00e3o de BPF) de IND\u00daSTRIA INTERNACIONAL de S\u00d3LIDOS N\u00c3O EST\u00c9REIS, exceto MERCOSUL”,
\n “Certificate Type”: “CBPF”,
\n “Expiration Date”: “29\/10\/2026”,
\n “Publication Date”: “29\/10\/2024”,
\n “Date of Resolution”: “24\/10\/2024”,
\n “Resolution”: “3.976”,
\n “Certificate Issued by”: “APROVA\u00c7\u00c3O T\u00c1CITA ?”,
\n “N.DOU”: “209”,
\n “GMP certificate Expiration Alert”: “No alerts”
\n },
\n {
\n “Certified Company”: “UNICHEM LABORATORIES LIMITED”,
\n “Code. Unique \/ Certified CNPJ”: “A000621”,
\n “Certified Company Address”: “C-31 & 32 & D-10, INDUSTRIAL AREA, MEERUT ROAD, GHAZIABAD 201 003”,
\n “Country”: “\u00cdNDIA”,
\n “Requesting Company”: “TORRENT DO BRASIL LTDA”,
\n “CNPJ (Requesting Company)”: “33.078.528\/0001-32”,
\n “Requesting Company Address”: “AVENIDA TAMBOR\u00c9, N\u00b0 1180, M\u00d3DULOS A3, A4, A5 E A6.”,
\n “City \/ State”: “BARUERI \/ SP”,
\n “Subject”: “70512 – MEDICAMENTOS \u2013 RENOVA\u00c7\u00c3O (Certifica\u00e7\u00e3o de BPF) de IND\u00daSTRIA INTERNACIONAL de S\u00d3LIDOS N\u00c3O EST\u00c9REIS, exceto MERCOSUL”,
\n “Certificate Type”: “CBPF”,
\n “Expiration Date”: “22\/01\/2026”,
\n “Publication Date”: “22\/01\/2024”,
\n “Date of Resolution”: “18\/01\/2024”,
\n “Resolution”: “211”,
\n “Certificate Issued by”: “APROVA\u00c7\u00c3O T\u00c1CITA ?”,
\n “N.DOU”: “15”,
\n “GMP certificate Expiration Alert”: “Your GMP certificate is expiring on 22\/01\/2026 (in 9 months or less). Please renew it.”
\n },
\n {
\n “Certified Company”: “NATCO PHARMA LIMITED”,
\n “Code. Unique \/ Certified CNPJ”: “A001421”,
\n “Certified Company Address”: “PLOT NO. 89 E 90, JNPC, RAMKY PHARMA CITY, PARAWADA VISAKHAPATNAM-531019,ANDHRA PRADESH”,
\n “Country”: “\u00cdNDIA”,
\n “Requesting Company”: “TORRENT DO BRASIL LTDA”,
\n “CNPJ (Requesting Company)”: “33.078.528\/0001-32”,
\n “Requesting Company Address”: “AVENIDA TAMBOR\u00c9, N\u00b0 1180, M\u00d3DULOS A3, A4, A5 E A6.”,
\n “City \/ State”: “BARUERI \/ SP”,
\n “Subject”: “769 – MEDICAMENTOS – (Certifica\u00e7\u00e3o de BPF) de IND\u00daSTRIA INTERNACIONAL de S\u00d3LIDOS N\u00c3O EST\u00c9REIS, exceto MERCOSUL”,
\n “Certificate Type”: “CBPF”,
\n “Expiration Date”: “04\/11\/2026”,
\n “Publication Date”: “04\/11\/2024”,
\n “Date of Resolution”: “31\/10\/2024”,
\n “Resolution”: “4.073”,
\n “Certificate Issued by”: “AN\u00c1LISE DE RISCO ?”,
\n “N.DOU”: “213”,
\n “GMP certificate Expiration Alert”: “No alerts”
\n },
\n {
\n “Certified Company”: “ATHENA DRUG DELIVERY SOLUTIONS PVT. LTD.”,
\n “Code. Unique \/ Certified CNPJ”: “A001229”,
\n “Certified Company Address”: “PLOT NO. A-1 TO A-5, MIDC, CHEMICAL ZONE, AMBERNATH (W), THANE 421501, MAHARASHTRA STATE”,
\n “Country”: “\u00cdNDIA”,
\n “Requesting Company”: “TORRENT DO BRASIL LTDA”,
\n “CNPJ (Requesting Company)”: “33.078.528\/0001-32”,
\n “Requesting Company Address”: “AVENIDA TAMBOR\u00c9, N\u00b0 1180, M\u00d3DULOS A3, A4, A5 E A6.”,
\n “City \/ State”: “BARUERI \/ SP”,
\n “Subject”: “70512 – MEDICAMENTOS \u2013 RENOVA\u00c7\u00c3O (Certifica\u00e7\u00e3o de BPF) de IND\u00daSTRIA INTERNACIONAL de S\u00d3LIDOS N\u00c3O EST\u00c9REIS, exceto MERCOSUL”,
\n “Certificate Type”: “CBPF”,
\n “Expiration Date”: “21\/10\/2026”,
\n “Publication Date”: “21\/10\/2024”,
\n “Date of Resolution”: “17\/10\/2024”,
\n “Resolution”: “3.860”,
\n “Certificate Issued by”: “APROVA\u00c7\u00c3O T\u00c1CITA ?”,
\n “N.DOU”: “204”,
\n “GMP certificate Expiration Alert”: “No alerts”
\n },
\n {
\n “Certified Company”: “LABORATORIOS LICONSA S.A.”,
\n “Code. Unique \/ Certified CNPJ”: “A000705”,
\n “Certified Company Address”: “AVDA. MIRALCAMPO, 7, POL. IND. MIRALCAMPO, AZUQUECA DE HENARES 19200 (GUADALAJARA)”,
\n “Country”: “ESPANHA”,
\n “Requesting Company”: “TORRENT DO BRASIL LTDA”,
\n “CNPJ (Requesting Company)”: “33.078.528\/0001-32”,
\n “Requesting Company Address”: “AVENIDA TAMBOR\u00c9, N\u00b0 1180, M\u00d3DULOS A3, A4, A5 E A6.”,
\n “City \/ State”: “BARUERI \/ SP”,
\n “Subject”: “70512 – MEDICAMENTOS \u2013 RENOVA\u00c7\u00c3O (Certifica\u00e7\u00e3o de BPF) de IND\u00daSTRIA INTERNACIONAL de S\u00d3LIDOS N\u00c3O EST\u00c9REIS, exceto MERCOSUL”,
\n “Certificate Type”: “CBPF”,
\n “Expiration Date”: “22\/04\/2027”,
\n “Publication Date”: “22\/04\/2025”,
\n “Date of Resolution”: “16\/04\/2025”,
\n “Resolution”: “1.503”,
\n “Certificate Issued by”: “RENOVA\u00c7\u00c3O AUTOM\u00c1TICA ?”,
\n “N.DOU”: “75”,
\n “GMP certificate Expiration Alert”: “No alerts”
\n }
\n]\n\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\n<\/div>\n\t\t<\/div>\n\n\t\t\n